• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

OBSERVE MEDICAL ASA: Mandatory notification of trades by primary insiders and close associate

OBSRVRegulatory press release2026-04-09 13:40
Oslo, 9 April 2026

Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has
been informed that Glimt Invest AS, a close associate of Terje Bakken, Chairman
of the Board and primary insider of the Company, has purchased 182,000 shares in
the Company.

Jørgen Mann, Chief Executive Officer of the Company, has purchased 50,000 shares
in the Company.

Johan Fagerli, Chief Financial Officer of the Company, has purchased 30,000
shares in the Company.

For further details, please refer to the attached notification forms.

This information is subject to the disclosure requirements pursuant to Article
19 of the EU Market Abuse Regulation and Section 5-12 of the Norwegian
Securities Trading Act.